Skip to main content
    I

    Icecure Medical (ICCM)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.04
    +0.00 (+0.00%)

    Market Cap: $5.10M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(10/18)
    Avg Surprise
    -7.40%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.83
    Range$-0.83 - $-0.83
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.88+5.7%
    60d ago$-0.88+5.7%
    30d ago$-0.830.0%
    7d ago$-0.830.0%
    Current$-0.83
    Revenue Consensus
    $876500
    Range$850000 - $903000
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-2.37
    Range$-2.37 - $-2.37
    1 analysts
    Revenue Consensus
    $623840
    Range$550840 - $696840
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-2.37---
    Sep 26EST
    		-$-0.83---
    Jun 26
    Reported Aug 12
    		$-3.11$-1.37-127.01%Miss-72.8%
    Mar 26
    Reported May 12
    		$-0.06$-0.05-16.20%Miss+96.8%
    Dec 25
    Reported Mar 17
    		$-1.80$-1.20-50.00%Miss-2150.0%
    Sep 25
    Reported Nov 19
    		$-1.80$-1.65-9.09%Miss+25.0%
    Jun 25
    Reported Aug 13
    		$-1.80$-1.95+7.69%Beat+0.0%
    Mar 25
    Reported May 28
    		$-1.80$-2.40+25.00%Beat+25.0%
    Dec 24
    Reported Mar 27
    		$-0.08$-0.08+0.00%Beat-33.3%
    Sep 24
    Reported Nov 26
    		$-2.40$-2.25-6.67%Miss+8.0%
    Jun 24
    Reported Aug 20
    		$-1.80$-2.10+14.29%Beat+31.8%
    Mar 24
    Reported Apr 3
    		$-2.40$-2.40+0.00%Beat+0.0%
    Dec 23
    Reported Feb 20
    		$-0.06$-0.08+21.77%Beat+45.5%
    Sep 23
    Reported Nov 15
    		$-2.61$-2.70+3.33%Beat+20.9%
    Jun 23
    Reported Aug 14
    		$-2.64$-2.60-1.54%Miss+29.0%
    Mar 23
    Reported May 22
    		$-2.40$-2.80+14.29%Beat-2100.0%
    Dec 22
    Reported Mar 29
    		$-0.11$-0.10-10.00%Miss-21.5%
    Sep 22
    Reported Dec 5
    		$-3.30$-3.45+4.35%Beat-4136.2%
    Jun 22
    Reported Aug 15
    		$-3.72$-3.60-3.33%Miss-4675.4%
    Mar 22
    Reported Apr 1
    		$0.12$0.12+0.00%Beat+263.7%
    Jun 21
    Reported Sep 23
    		$-0.09$0.00N/AMiss-0.9%
    Mar 21
    Reported Apr 12
    		$-0.08$0.00N/AMiss-46.4%
    Dec 20
    Reported Mar 31
    		$-0.08$0.00N/AMiss-46.4%
    Sep 20
    Reported Dec 31
    		$-0.07$0.00N/AMiss+7.1%
    Jun 20
    Reported Sep 30
    		$-0.09$0.00N/AMiss-14.4%
    Mar 20
    Reported Jun 30
    		$-0.05$0.00N/AMiss+43.6%
    Dec 19
    Reported Mar 30
    		$-0.05$0.00N/AMiss+42.7%
    Sep 19
    Reported Dec 31
    		$-0.08$0.00N/AMiss-3.4%
    Jun 19
    Reported Sep 30
    		$-0.08$0.00N/AMiss+10.4%
    Mar 19
    Reported Jun 30
    		$-0.09$0.00N/AMiss-9.4%
    Dec 18
    Reported Mar 30
    		$-0.09$0.00N/AMiss+16.3%
    Sep 18
    Reported Dec 31
    		$-0.08$0.00N/AMiss+37.9%
    Mar 18
    Reported Jun 30
    		$-0.09$0.00N/AMiss+21.5%
    Dec 17
    Reported Mar 30
    		$-0.09$0.00N/AMiss+97.7%
    Sep 17
    Reported Dec 31
    		$-0.11$0.00N/AMiss-
    Jun 17
    Reported Sep 30
    		$-0.12$0.00N/AMiss-
    Mar 17
    Reported Jun 30
    		$-0.11$0.00N/AMiss-
    Dec 16
    Reported Mar 30
    		$-3.81N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.15EV/EBITDAN/A
    Price/FCF-0.20xFCF Yield-510.53%
    Profitability
    Profit Margin0.00%Operating Margin-487.80%
    ROE-228.30%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-106.52x
    Current Ratio2.87xQuick Ratio2.44x
    Trading Statistics
    Beta0.43Avg Volume179.52K
    52-Week High$25.7952-Week Low$0.96

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.20
    SMA 20$1.49
    SMA 50$2.08
    SMA 200$8.96
    EMA 10$1.21
    EMA 20$1.45
    EMA 50$2.16
    EMA 200$8.60

    MACD

    Line: -0.32Signal: -0.30Hist: -0.01

    ADX

    ADX: 33.4+DI: 8.8-DI: 28.5

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down96.0
    PSAR$1.17

    Bollinger Bands

    Upper Band$2.16
    Lower Band$0.81
    %B Position9089%(Upper)
    Band Width0.17

    RSI (14-Day)

    Oversold
    15.9

    Momentum Oscillators

    Stoch %K8.5
    Stoch %D7.1
    Williams %R-90.7
    ROC (10d)-38.5%
    Momentum-0.65
    CCI (20d)-102.0
    MFI (14d)16.9

    Volatility Measures

    ATR (14d)$0.18(17.3%)
    StdDev (20d)0.34
    Hist Vol77.0%(High)

    Volume Flow

    VWAP$1.04
    OBV179.8M
    AD Line178.3B
    CMF (20d)-0.365

    Volume Metrics

    Avg Vol (20d)185.4K
    Vol Ratio0.5x
    VWMA (20d)$1.40

    Pivot Points

    R3$1.23
    R2$1.16
    R1$1.10
    Pivot Point$1.03
    S1$0.97
    S2$0.90
    S3$0.84

    Advanced Oscillators

    TSI-64.36
    Ultimate Osc36.1
    KST-425.50

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$907,000$911,000$1.28M$850,000$525,000$725,000$875,000$662,000$1.01M$743,000$1.25M$327,000
    Cost of Revenue$654,000$616,000$679,000$573,000$394,000$507,000$458,000$427,000$481,000$474,000$686,000$350,000
    Gross Profit$253,000$295,000$600,000$277,000$131,000$218,000$417,000$235,000$530,000$269,000$569,000$-23,000
    Operating Expenses$-4,171,000$4.54M$4.82M$18.20M$3.52M$3.88M$4.94M$4.53M$3.76M$3.92M$4.67M$4.10M
    R&D$2.07M$2.21M$2.30M$1.76M$1.71M$1.66M$1.70M$1.86M$1.58M$1.95M$1.88M$2.20M
    SG&A$1.16M$1.26M$4.54M$1.44M$2.67M$922,000$992,000$918,000$915,000$930,000$2.10M$919,000
    Operating Income$4.42M$-4,247,000$-4,216,000$-17,920,000$-3,385,000$-3,657,000$-4,525,000$-4,293,000$-3,228,000$-3,650,000$-3,415,000$-4,123,000
    Interest Income$0$0$0$0$21,000$69,000$0$0$0$41,000$0$0
    Interest Expense$77,000$27,000$30,000$23,000$0$0$0$0$0$0$0$0
    Income Before Tax$-4,501,000$-4,274,000$-4,246,000$-3,859,000$-3,364,000$-3,588,000$-4,479,000$-4,149,000$-3,081,000$-3,609,000$-2,995,000$-4,000,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$43,558$0$121,586
    Net Income$-4,501,000$-4,274,000$-4,246,000$-3,859,000$-3,364,000$-3,588,000$-4,479,000$-4,149,000$-3,081,000$-3,609,000$-2,995,000$-4,000,000
    EBITDA$-4,353,000$-4,178,000$-4,145,000$-3,763,000$-3,323,000$-3,568,000$-4,443,000$-4,210,000$-3,146,000$-3,691,000N/A$-4,041,000
    EBIT$-4,424,000$-4,247,000$-4,216,000$-3,836,000$-3,385,000$-3,657,000$-4,525,000$-4,293,000$-3,228,000$-3,419,370N/A$-4,121,335
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ICCM

    News

    Forty patients got breast cancer freezing plus hormone therapy. IceCure (ICCM) reports 12-month results.

    IceCure Medical Ltd. reported 12-month objective response rates for its ProSense® breast cancer cryoablation system at the European Society of Breast Imaging’s 2026 meeting. The company announced a 97.5% response rate...

    Stock Titan•10/13/26•Bullish

    IceCure Medical presents breast cryoablation data at EUSOBI meeting

    IceCure Medical announced that its ProSense® breast cancer cryoablation system was featured prominently at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting 2026. The presentations included...

    StreetInsider•10/13/26•Bullish

    IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026

    IceCure Medical announced strong physician engagement and clinical data for its ProSense® breast cancer cryoablation technology at the EUSOBI 2026 Annual Scientific Meeting. The event featured multiple presentations...

    PR Newswire•10/13/26•Neutral

    At 12 months, tumor-freezing plus hormone therapy had a 97.5% response rate in 40 breast cancer patients.

    IceCure Medical presented promising 12-month clinical data for its ProSense breast cancer cryoablation technology at the EUSOBI 2026 meeting. The data showed a 97.5% objective response rate in 40 patients treated...

    Stock Titan•10/13/26•Bullish

    IceCure adds Legacy Health in Portland to breast cancer cryoablation study

    IceCure Medical Ltd. has expanded its ProSense® ChoICE Study by adding Legacy Health in Portland, Oregon, as a new U.S. clinical site. This post-marketing trial evaluates cryoablation as a minimally invasive treatment...

    StreetInsider•10/6/26•Bullish

    ICCM Valuation and Fair Value

    P/E
    -0.2x
    P/FCF
    -0.2x
    P/B
    0.3x
    See GNG's fair value

    ICCM Profitability: Margins, ROIC and FCF

    Gross margin
    36.1%
    Operating margin
    -487.8%
    Net margin
    0.0%
    ROE
    -228.3%
    FCF margin
    -415.2%
    FCF yield
    -510.5%

    ICCM Competitors

    CompanyTicker
    Trinity Biotech plcTRIB
    Pulmatrix IncPULM
    Aptorum Group Ltd Class AAPM
    Sonnet Biotherapeutics Holdings IncSONN
    Processa Pharmaceuticals IncPCSA
    Biomx IncPHGE
    Volitionrx LtdVNRX
    Kala Pharmaceuticals IncKALA

    Sector: Healthcare

    ICCM Analyst Ratings

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    1
    Buy
    2
    Hold
    0
    Sell
    0
    Strong Sell
    0

    ICCM Bull Case vs Bear Case

    Bull case

    • ICCM grew quarterly revenue 72.8% year over year.

    Bear case

    • ICCM beat EPS estimates in 25.0% of its last 8 reported quarters.

    ICCM Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -22.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.83
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About ICCM

    Does ICCM pay dividends?

    Icecure Medical (ICCM) does not currently pay a regular dividend.

    What is ICCM's market cap?

    Icecure Medical (ICCM) has a market capitalization of $5.10M with a current stock price of $1.04.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In